26 The RNAi assessment of bevasiranib (OPKO Health Inc., Ontario, Canada) in DME (RACE) trial was a phase II investigation of the preliminary efficacy and safety of bevasiranib and showed a trend toward decreasing macular thickness with a dose-dependent effect. 27 Numerous other molecules have also been identified as inhibitors of angiogenesis, including pigment epithelium-derived factor (PEDF), and have become targets for the development of anti-angiogenic medications. 28 Pigment epitheliu
1
—
—